Background
Prospective data on neonatal outcome following in utero exposure to antirerovirals (ARVs) are essential components of safety monitoring of these life-saving therapies. Toward this end, APR was created in 1989 and is now one of the largest ongoing pregnancy registries in the world.
Methods
APR is an international registry that uses a prospective exposure-registration cohort design to monitor potential birth defects following in utero ARV exposure. Health care providers voluntarily enroll exposed pregnant women, then provide follow-up neonatal data. We analyzed APR data for their ability to detect, at 80% power with Type I error rate of 5%, potential increases in birth defect prevalence following fetal 1st trimester (TRI) exposure (when organogenesis occurs), vs. 2nd and 3rd TRI exposures.
Summary of results
By January 2008, APR received 11,209 prospective reports. Of these, 9,400 live birth (LB) outcomes were available, including 3,951 LB following 1st TRI exposures. These reports allow detection of a potential 1.5-fold increase in overall anomalies following 1st TRI exposure to any ARV compared to 2nd/3rd TRI exposures. We found no such increase. Birth defect prevalence after any 1st TRI ARV exposure was 3.0% vs. 2.6% following any 2nd/3rd TRI ARV exposure (1.13 relative risk, 95% CI = 0.89, 1.43). Twelve individual drugs have >200 1st TRI reports and allow us to detect a potential 1.5-2-fold increase in all defects for each agent (Table 1) . Such an increase has not been found.
Two drugs met the threshold for evaluation and further monitoring: zidovudine was associated with an increased risk of hypospadius [1] , and a higher than expected defect prevalence following didanosine exposure that has no apparent pattern and is not statistically significant [2] .
Conclusion
In summary, prospectively collected APR data have not detected an overall increase in birth defects following in utero ARV exposure during organogenesis. We continue to follow two trends that do not reach statistical significance. 
